Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture

N Engl J Med. 2024 Oct 24;391(16):1499-1510. doi: 10.1056/NEJMoa2312631. Epub 2024 Oct 9.

Abstract

Background: Treatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.

Methods: We performed an unblinded, multicenter, pragmatic, two-group, randomized, controlled noninferiority trial comparing collagenase injection with limited fasciectomy in persons with moderate Dupuytren's contracture. The primary outcome was the score on the Patient Evaluation Measure-Hand Health Profile (PEM), a questionnaire for assessing hand health as reported by the patient, at 1 year after treatment. Scores on the PEM range from 0 to 100, with higher scores indicating worse outcomes. The prespecified noninferiority margin was 6 points.

Results: A total of 672 persons (336 per group) were assigned to receive collagenase injection or to undergo limited fasciectomy. The primary analysis included 599 persons: 314 in the collagenase group and 285 in the limited-fasciectomy group. The mean score on the PEM at 1 year was 17.8 among the 284 patients with available data in the collagenase group and 11.9 among the 250 patients with available data in the limited-fasciectomy group (estimated difference, 5.9 points; 95% confidence interval [CI], 3.1 to 8.8; one-sided P = 0.49 for noninferiority). Among the patients with available data (229 patients in the collagenase group and 197 patients in the limited-fasciectomy group), the estimated difference in the mean score on the PEM at 2 years was 7.2 points (95% CI, 4.2 to 10.9). Moderate or severe complications of treatment occurred in 1.8% of the patients in the collagenase group and in 5.1% of those in the limited-fasciectomy group; recurrent contracture resulted in reintervention in 14.6% and 3.4%, respectively.

Conclusions: Collagenase injection was not noninferior to limited fasciectomy with respect to the score on the PEM at 1 year after treatment. (Funded by the National Institute for Health and Care Research Health Technology Assessment Programme; DISC ISRCTN Registry number ISRCTN18254597.).

Publication types

  • Clinical Trial, Phase IV
  • Comparative Study
  • Equivalence Trial
  • Multicenter Study
  • Pragmatic Clinical Trial

MeSH terms

  • Aged
  • Collagenases* / administration & dosage
  • Collagenases* / adverse effects
  • Collagenases* / economics
  • Cost-Effectiveness Analysis
  • Dupuytren Contracture* / diagnosis
  • Dupuytren Contracture* / drug therapy
  • Dupuytren Contracture* / economics
  • Dupuytren Contracture* / surgery
  • Fasciotomy* / economics
  • Fasciotomy* / statistics & numerical data
  • Female
  • Humans
  • Injections, Intralesional*
  • Male
  • Microbial Collagenase / administration & dosage
  • Microbial Collagenase / adverse effects
  • Microbial Collagenase / therapeutic use
  • Middle Aged
  • Recurrence
  • Retreatment / statistics & numerical data

Substances

  • Collagenases
  • Microbial Collagenase

Associated data

  • ISRCTN/ISRCTN18254597